BEST-MS: A prospective head-to-head comparative study of natalizumab and fingolimod in active relapsing MS. Cohen M, Mondot L, Bucciarelli F, Pignolet B, et al. Mult Scler 2021;27:1556-1563.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Cohen M, Mondot L, Bucciarelli F, Pignolet B, et al. BEST-MS: A prospective head-to-head comparative study of natalizumab and fingolimod in active relapsing MS. Mult Scler 2021;27:1556-1563.
PMID: 33124504